Cascades Inc
OTC:CADNF
Cascades Inc
Cascades, Inc. produces, converts and markets packaging and tissue products composed mainly of recycled fibres. The company is headquartered in Kingsey Falls, Quebec and currently employs 10,000 full-time employees. The Company’s segments include Containerboard, Specialty Products (which constitutes the Company's Packaging Products) and Tissue Papers. The Containerboard segment is a manufacturer of containerboard and converter of corrugated products in North America. The Specialty Products Group manufactures industrial and food packaging products. The Tissue Papers segment manufactures tissue paper reels and converts them into finished products for the professional and residential markets. The firm also provides recycling solutions. The company operates approximately 80 production units throughout North America.
Cascades, Inc. produces, converts and markets packaging and tissue products composed mainly of recycled fibres. The company is headquartered in Kingsey Falls, Quebec and currently employs 10,000 full-time employees. The Company’s segments include Containerboard, Specialty Products (which constitutes the Company's Packaging Products) and Tissue Papers. The Containerboard segment is a manufacturer of containerboard and converter of corrugated products in North America. The Specialty Products Group manufactures industrial and food packaging products. The Tissue Papers segment manufactures tissue paper reels and converts them into finished products for the professional and residential markets. The firm also provides recycling solutions. The company operates approximately 80 production units throughout North America.
Strong Quarter: Cascades delivered better-than-expected Q3 results, driven by higher volumes, improved selling prices, and lower production costs.
Profitability Momentum: Consolidated EBITDA rose 16% sequentially and 14% year-over-year, reflecting benefits from ongoing profitability initiatives.
Packaging Outperformance: Packaging EBITDA increased 14% from Q2 with margins rising to 17.1%; Bear Island ramp-up and Niagara Falls closure both progressed ahead of plan.
Tissue Improvements: Tissue EBITDA rose 21% sequentially, aided by stronger volumes and lower operating costs.
Debt Reduction: Net debt fell by $81 million in Q3, and the company is prioritizing free cash flow for further debt repayment.
Asset Monetization Target Raised: Asset sale target was increased to $120 million by mid-2026, up from $80 million previously.
Q4 Outlook Cautious: Packaging results are expected to be flat to down 10% in Q4 due to anticipated seasonal volume declines and macro uncertainty; Tissue expected to strengthen.
Profitability Initiatives: Company on track for $100 million run rate improvement by end of 2026, with $10 million contributed in Q3.
